In a report released today, Jason Seidl from Cowen & Co. maintained a Buy rating on CryoPort Inc (Other OTC: CYRX), with a price target of $16. The company’s shares closed on Friday at $15.26, close to its 52-week high of $16.88.
According to TipRanks.com, Seidl is a top 100 analyst with an average return of 19.0% and a 73.2% success rate. Seidl covers the Services sector, focusing on stocks such as Covenant Transportation Group, Expeditors International, and Echo Global Logistics.
CryoPort Inc has an analyst consensus of Strong Buy, with a price target consensus of $19.
See today’s analyst top recommended stocks >>
Based on CryoPort Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $2.47 million. In comparison, last year the company had a GAAP net loss of $1.86 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Lake Forest, CA.
